Alx Oncology Holdings (ALXO) Cash from Operations (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Cash from Operations data on file, last reported at 18648000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 24.39% year-over-year to 18648000.0; the trailing twelve-month figure through Mar 2026 stood at 78127000.0 (up 28.09% YoY), and the FY2025 full-year result was 84142000.0, up 30.98% from the prior year.
• Cash from Operations advanced to 18648000.0 in Q1 2026, from 18980000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 16998000.0 in Q2 2022 to a low of 39678000.0 in Q4 2023.
• A 5-year average of 26134647.06 and a median of 25376000.0 in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations tumbled 302.61% in 2022 and surged 40.77% in 2025, its largest moves.
• Tracing ALXO's Cash from Operations over 5 years: stood at 20668000.0 in 2022, then sank by 91.98% to 39678000.0 in 2023, then grew by 19.23% to 32046000.0 in 2024, then jumped by 40.77% to 18980000.0 in 2025, then gained by 1.75% to 18648000.0 in 2026.
• Business Quant data shows ALXO's Cash from Operations at 18648000.0 in Q1 2026, 18980000.0 in Q4 2025, and 17093000.0 in Q3 2025.